Bellerophon Therapeutics, Inc. announced that Peter Fernandes, the Company?s Chief Executive Officer, set November 15, 2023 as the separation date for the employment. On November 15, 2023, the Board appointed Craig Jalbert, age 62, as the company's President, Treasurer and Corporate Secretary and as the Company?s principal executive officer, principal financial officer and principal accounting officer, effective November 15, 2023, and as a member of the Board, effective November 15, 2023, to serve until the next election of directors and thereafter until his successor has been elected and qualified or until his earlier death, resignation or removal. Mr. Jalbert has not been appointed to any committee of the Board and as of the date hereof is not expected to be appointed to any committee of the Board.

Mr. Jalbert has served as a principal of the Foxborough, Massachusetts accounting firm of Verdolino & Lowey, P.C. since 1987. For over 30 years he has focused his practice on distressed businesses and has served, and continues to serve, in the capacities of officer and director for numerous firms in their wind-down phases.